Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philip Mease

Showing results (51-60 of 174) with videos related to

Pageof 18
Sort By:
Pain Medicine (Malden, Mass.)|December 17, 2009
Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension studyDon L Goldenberg, Daniel J Clauw, Robert H Palmer, et al.
Annals of the Rheumatic Diseases|October 13, 2011
Application of composite disease activity scores in psoriatic arthritis to the PRESTA data setOliver FitzGerald, Philip Helliwell, Philip Mease, et al.
Journal of Managed Care & Specialty Pharmacy|April 12, 2021
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visitA Mark Fendrick, Diana Brixner, David T Rubin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2014
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritisPhilip Mease, Joachim Sieper, Filip Van den Bosch, et al.
Arthritis and Rheumatism|March 27, 2013
Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active diseaseLaura C Coates, Oliver FitzGerald, Dafna D Gladman, et al.
Psychosomatic Medicine|July 4, 2012
The effect of duloxetine treatment on cognition in patients with fibromyalgiaRichard Mohs, Philip Mease, Lesley M Arnold, et al.
Annals of the Rheumatic Diseases|March 28, 2013
Documentation of off-label use of biologics in Rheumatoid ArthritisDaniel E Furst, Roy Fleischman, Joachim Kalden, et al.
Rheumatology and Therapy|September 25, 2024
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical TrialsPhilip Mease, Tatiana Korotaeva, Pavel Shesternya, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
Pain Medicine (Malden, Mass.)|September 11, 2012
Burden of illness and treatment patterns for patients with fibromyalgiaRebecca L Robinson, Kurt Kroenke, Philip Mease, et al.
Pageof 18

Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Pain Medicine (Malden, Mass.)|December 17, 2009
Durability of therapeutic response to milnacipran treatment for fibromyalgia. Results of a randomized, double-blind, monotherapy 6-month extension studyDon L Goldenberg, Daniel J Clauw, Robert H Palmer, et al.
Annals of the Rheumatic Diseases|October 13, 2011
Application of composite disease activity scores in psoriatic arthritis to the PRESTA data setOliver FitzGerald, Philip Helliwell, Philip Mease, et al.
Journal of Managed Care & Specialty Pharmacy|April 12, 2021
Sustained long-term benefits of patient support program participation in immune-mediated diseases: improved medication-taking behavior and lower risk of a hospital visitA Mark Fendrick, Diana Brixner, David T Rubin, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 30, 2014
Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritisPhilip Mease, Joachim Sieper, Filip Van den Bosch, et al.
Arthritis and Rheumatism|March 27, 2013
Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active diseaseLaura C Coates, Oliver FitzGerald, Dafna D Gladman, et al.
Psychosomatic Medicine|July 4, 2012
The effect of duloxetine treatment on cognition in patients with fibromyalgiaRichard Mohs, Philip Mease, Lesley M Arnold, et al.
Annals of the Rheumatic Diseases|March 28, 2013
Documentation of off-label use of biologics in Rheumatoid ArthritisDaniel E Furst, Roy Fleischman, Joachim Kalden, et al.
Rheumatology and Therapy|September 25, 2024
Guselkumab in Biologic-Naïve Patients with Active Psoriatic Arthritis in Russia: A Post Hoc Analysis of the DISCOVER-1 and -2 Randomized Clinical TrialsPhilip Mease, Tatiana Korotaeva, Pavel Shesternya, et al.
Journal of Managed Care & Specialty Pharmacy|May 14, 2019
Patient Support Program Increased Medication Adherence with Lower Total Health Care Costs Despite Increased Drug SpendingDiana Brixner, David T Rubin, Philip Mease, et al.
Pain Medicine (Malden, Mass.)|September 11, 2012
Burden of illness and treatment patterns for patients with fibromyalgiaRebecca L Robinson, Kurt Kroenke, Philip Mease, et al.
Pageof 18